Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease

Shilpa Chitnis, Manall Jaffery, Richard B. Dewey

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Background: When rotigotine patch was withdrawn from the US market, we prospectively gathered data on efficacy, side effects, and daytime sedation on patients while taking rotigotine and following the switch to alternate therapies. Methods: Patients rated the efficacy of rotigotine on a scale of 05 (ineffective to extremely effective) and completed the Epworth Sleepiness Scale. At a follow-up visit a mean of 3 months later, patients rated their change in efficacy and side effects on a scale of -3 to +3 (much worse to much better) and again completed the Epworth Sleepiness Scale. Results: Thirty-three patients were switched to a single alternate treatment. On rotigotine, the average efficacy score was 3.5, and after switching, the average change in efficacy was -0.67 (worsening). Average change scores for efficacy and adverse effects were 0.25 and 0.38 for levodopa, -0.88 and -0.25 for ropinirole IR, -1.2 and -0.83 for ropinirole XL, -0.80 and 1.0 for pramipexole, and -1.0 and 0.50 for rasagiline, respectively. Average change in Epworth score on each alternate agent was -3.9, -2.3, 1.3, 3.0, and 1. Conclusion: Rotigotine was an effective treatment with all groups deteriorating after switch except for the levodopa group. Fifty-eight percent of patients preferred rotigotine versus 36% preferring the alternate treatment.

Original languageEnglish (US)
Pages (from-to)22-25
Number of pages4
JournalInternational Journal of Neuroscience
Issue number1
StatePublished - Jan 2012


  • Alternate therapies
  • Parkinson's disease
  • Rotigotine

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease'. Together they form a unique fingerprint.

Cite this